Neuroscientist Gary Gibson, Ph.D. ’73, keeps a framed picture of a cell derived from the skin cells of a person with Alzheimer’s disease on his office wall.
The image is a memento of Gibson’s breakthrough…
A multicenter randomized, controlled clinical trial aims to test whether a minimally invasive treatment can relieve chronic pelvic pain and improve the quality of life for women with pelvic venous disease.
Reinforcement Learning, an artificial intelligence approach, has the potential to guide physicians in designing sequential treatment strategies for better patient outcomes but requires significant improvements before it can be applied in clinical settings.
Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.
A newer hepatitis B vaccine was superior to an older type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to a study led by a Weill Cornell Medicine investigator.
Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
Many individuals seeking asylum in the United States show increased stress and pain symptoms that are associated with indications of cardiovascular disease, according to Weill Cornell Medicine researchers.
Specially packaged DNA secreted by tumor cells can trigger an immune response that inhibits the metastatic spread of the tumor to the liver, according to a study led by researchers at Weill Cornell Medicine.
